our partners

101 6th Ave,
New York, NY 10013


Cambridge Innovation Center
1 Broadway 
Cambridge, MA 02142


© 2019 A2A Pharma. All rights reserved



​Harvard Medical School, Bayer, Novartis, Celgene, CMO of Ipsen

  • Chief Medical Officer, SVP and Head of Global Medical Affairs at Ipsen

  • Vice President and Head of Global Medical Affairs Oncology for Baxalta Inc and Shire & roles in medical affairs and clinical development at Bayer Pharmaceuticals, Novartis Pharmaceuticals and Celgene Corporation 

  • Trained in Internal Medicine and Cancer Genetics from NIH, Albert Einstein College of Medicine and Harvard Medical School

  • Masters of Biotechnology Enerprise and Entrepreneurship from Johns Hopkins University

President & CEO, Founder

Sotirios Stergiopoulos, MD, MBEE, FACP


Research and Biotech focused capital markets with Goldman Sachs, Credit Suisse & UBS​

  • MBA from University of Illinois at Urbana-Champaign

  • Former VP at UBS, Oppenheimer & Co., Credit Suisse, and Kidder Peabody

  • Former analyst at Goldman Sachs and Salomon Brothers

  • 30 years of experience in finance

  • Has worked extensively with biotech companies in financing and investment decisions

Chairman & CIO, Founder

Edward Painter, MBA


Medicinal Chemist. Trinity College Dublin, University of Toronto. Consultant and Venture Advisor

  • Life Science Innovation Specialist with over 8 years of experience in the USA, Canada and Europe Life Science markets.

  • Experienced in consulting for tier-1 pharma companies and project management for several innovation organizations in North America.

  • Venture advisor and business developer for diverse biotechnology companies.

  • Ph.D. medicinal chemistry in the synthesis and bio-evaluation of protein kinase inhibitors for the treatment of cancer at Trinity College Dublin.

  • Postdoctoral research in Neuroscience at University of Toronto and part-time professorship at San Francisco State University.

Head of Business Development, R&D Strategy

Elena Diez Cecilia, PhD, MBA


Medicinal and Computational Chemist. Seoul National University, University of Pittsburgh, UPCDC ​

  • PhD in Synthetic and Medicinal Chemistry from the Seoul National University

  • Postdoctoral research in Chemistry from the University of Pittsburgh

  • Extensive research experience in synthetic organic chemistry and drug discovery covering multiple therapeutic areas

  • Co-authored 20 SCI papers and 9 patent applications as a co-inventor

  • Has contributed to drug discovery and development projects ranging from early development stages through to preclinical trials particularly using in silico drug design tools

Chief Scientific Officer

Chaemin Lim, PhD

Machine Learning and Computational Chemist 

  • Master in Computer Science, Cornell Tech

  • Chemist, Univ. South Florida

  • Bryd Alzheimers Institute, Center of Disease and Drug Innovation Medicinal Chemist

  • Development of Novel Therapeutics using Cannabinoid analogs for Alzheimer's and Other Neurodegenerative Diseases. 

Head of Technology Innovation

Emmanuel Cruz, M.Eng, B.S.

brendan kelly.jpeg

Stanford, University of Toronto, Trinity College Dublin. Consulting with Pfizer, Eli Lilly & currently at LEK

  • Ph.D. Design, synthesis & evaluation of alpha 2 adrenoceptor antagonists for the treatment of Depession

  • Postdoctoral research, Stanford University

  • Collaboration with Pfizer & Eli Lilly on multiple projects

  • Life Science Specialist at L.E.K. Consulting


Brendan Kelly, PhD

Screen Shot 2019-05-11 at 3.54.41 PM.png

Harvard University Postdoc Leukemia Research, BD Ironwood and Rafael Pharma​

  • PhD in Human Biology from Ludwig-Maximilians University

  • MBA from Boston University

  • Postdoctoral research at Harvard University in leukemia and the target of AO-001

  • Authored several articles in oncology in leading publications

  • Biotechnology industry analyst experience at Jeffries LLC 

Founder, Advisor

Sridhar Vempati

Machine Learning and Computational Chemist. University of Pittsburgh

  • PhD student from University of Pittsburgh

  • Drug design and compound development experiences in CNS disorders and cancer

  • In silico modeling and simulations with applications on drug discovery using fragment-based approach

  • MS in Pharmaceutical Science from University of Pittsburgh

Computational Chemist

Yuemin Bian, MSc